Corindus Vascular Robotics Launches Extensive Study of Robotic Angioplasty Effectiveness and Safety: stakes and opportunities.

With the final goal to collect data on the patterns of use, safety and effectiveness in the delivery and manipulation of percutaneous coronary intervention (PCI) devices, Corindus Vascular Robotics Launches Extensive Study of Robotic Angioplasty
Effectiveness and Safety. Dr. Giora Weisz, Associate Professor of Medicine at Columbia University Medical Center, will lead the study.

 “We have seen initial clinical indications linked to the benefits of robotics during the CorPath PRECISE clinical trial, published recently, and with the launch of the PRECISION Registry, we expect to see continued trending towards improved clinical output resulting from the routine practice of robotics during PCIs.” said Dr. Weisz.

Connectikpeople has observed that, Corindus’ CorPath 200 System aims to be the first and only FDA-cleared technology that enables precise, robotic-assisted angioplasties to open arteries and restore blood flow in patients with coronary artery disease; moreover, CorPath may improve clinical outcomes by enabling precise measurement of the anatomy.

“Corindus is committed to engaging clinical research and providing evidence-based claims related to the benefits of robotic angioplasty,” said David Handler, President and CEO of Corindus Vascular Robotics.

About Corindus Vascular Robotics

 Corindus Vascular Robotics is the global technology leader in robotic-assisted percutaneous coronary interventions (PCI). The Company’s FDA cleared CorPath^® 200 System is the first medical device that offers interventional cardiologists PCI procedure control from an interventional cockpit. The CorPath open-platform technology and intellectual property will enable Corindus to address other segments of the vascular market, including peripheral, neuro and structural heart applications.